Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.
Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.
Azitra (NYSE American: AZTR) adjourned its virtual Special Meeting held Feb 6, 2026, to March 6, 2026 at 11:00 a.m. ET because a quorum was not present. Proxies then represented approximately 13% of outstanding voting shares; a quorum requires 33 1/3%.
The Reconvened Special Meeting will consider two proposals: approval to issue more than 19.99% of outstanding common stock underlying warrants under a Nov 24, 2025 Purchase Agreement with Alumni Capital LP, and a potential adjournment to solicit additional proxies.
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT. Management will hold one-on-one meetings with registered investors and potential partners to review the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
The presentation will be delivered by Travis Whitfill, Chief Operating Officer, at the Hilton San Francisco Union Square (Yosemite C, Ballroom Level). Registration is available through the event website for accredited attendees.
Azitra (NYSE: AZTR) received NYSE American staff approval of its listing standards compliance plan under Section 1003(a)(ii).
Azitra previously received a notice for not meeting the $4.0 million minimum stockholders' equity requirement after reporting losses in three of the last four fiscal years. The company must regain compliance by April 1, 2027 or face potential delisting. Azitra will remain listed during monitoring and is exploring multiple funding avenues to achieve compliance.
Azitra (NYSE American: AZTR) entered a private placement with a single institutional investor to sell 4,687,500 shares of common stock (or pre-funded warrants in-lieu) together with warrants to purchase up to 4,687,500 shares.
The combined effective offering price per share plus warrant is $0.32, producing estimated gross proceeds of approximately $1.5 million before placement agent fees and expenses. The warrants have an exercise price of $0.32, will be exercisable upon shareholder approval, and expire five years after that approval. The Offering is expected to close on or about November 25, 2025. Maxim Group is sole placement agent. The company has agreed to file a resale registration statement with the SEC.
Azitra (NYSE American: AZTR) reported Q3 2025 results and business updates on Nov 12, 2025. Key operational highlights: dosed first patient in the Phase 1/2 ATR-04 trial for EGFRi-associated rash (Aug 2025) and presented positive preclinical data for ATR-01 at BIO-Europe. The company raised $2.8M under an equity line with Alumni Capital LP. Financials: R&D expense was $1.2M (Q3 2025) vs $1.0M (Q3 2024); G&A was $1.6M vs $1.9M; net loss was $2.8M vs $1.0M; cash and cash equivalents were $1.4M as of Sept 30, 2025.
The company said it continues to advance ATR-12, ATR-04, and ATR-01 programs derived from its topical live biotherapeutic platform.
Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.
Azitra (NYSE: AZTR) announced positive preclinical results for ATR-01 (ATR01-616), an engineered S. epidermidis strain designed to secrete functional human filaggrin to treat ichthyosis vulgaris.
Key findings reported: ATR01-616 secreted functional filaggrin in vitro, delivered filaggrin through the human stratum corneum (delivery below the barrier, p < 0.05), and significantly reduced transepidermal water loss in a damaged pig skin model (p < 0.002).
Azitra plans a path toward first-in-human studies and aims to submit an IND in 2026; detailed data will be presented at BIO-Europe, November 3–5, 2025.
Azitra (NYSE American: AZTR) announced that Travis Whitfill, Ph.D., co-founder and COO, will appear on a Dermatologic Rare Disease Panel at the Maxim Growth Summit in New York City on October 22, 2025 at 8:30 AM EDT.
The panel will discuss Netherton syndrome and Recessive Epidermolysis Bullosa (RDEB). Azitra's lead program, ATR-12, is in a Phase 1b trial in adult Netherton syndrome patients and uses an engineered strain of S. epidermidis to deliver LEKTI topically. Azitra also highlighted ATR-04, an engineered S. epidermidis program for EGFR inhibitor associated rash with FDA Fast Track designation and an open IND.
Azitra (NYSE American: AZTR) received a notice of non-compliance from NYSE American on October 3, 2025 under Section 1003(a)(ii).
The rule requires listed companies with recent losses to have $4 million or more in stockholders' equity. Azitra has until October 31, 2025 to file a Plan to regain compliance by April 1, 2027. The company says it will timely submit a Plan, is exploring multiple funding avenues, and intends to complete one or more transactions to achieve compliance. Receipt of the notice does not affect current listing or trading or SEC reporting.
Azitra is a clinical-stage dermatology company with lead programs ATR-12 (Phase 1b) and ATR-04 (FDA Fast Track; open IND) and a microbial library of ~1,500 strains.